Ansun BioPharma has appointed Stanley Lewis to serve as its chief medical officer. Lewis comes to Ansun from TaiMed Biologics, where as CMO he oversaw the development of a treatment for multi-drug resistant HIV through to FDA approval. San Diego-based Ansun said Lewis will oversee the late-stage development of its lead candidate, DAS181, a treatment for parainfluenza, which is poised to enter a Phase 3 program. Ansun also said it appointed Connie Lu to serve as its vice president of quality. Lu was previously at Genentech.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
